Serum microRNA-125a-5p, a useful biomarker in liver diseases, correlates with disease progression

Zheng,Jianjian; Zhou,Zhenxu; Xu,Ziqiang; Li,Guojun; Dong,Peihong; Chen,Zhanguo; Lin,Dezhao; Chen,Bicheng; Yu,Fujun

doi:10.3892/mmr.2015.3546

Serum microRNA-125a-5p, a useful biomarker in liver diseases, correlates with disease progression

Authors:
- Jianjian Zheng
- Zhenxu Zhou
- Ziqiang Xu
- Guojun Li
- Peihong Dong
- Zhanguo Chen
- Dezhao Lin
- Bicheng Chen
- Fujun Yu
View Affiliations

Affiliations: Wenzhou Key Laboratory of Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China, Department of Laparoscopic Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China, Institute of Organ Transplantation, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China, Department of Hepatology, Ningbo Yinzhou Second Hospital, Ningbo, Zhejiang 315000, P.R. China, Department of Infectious Diseases, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China, Centre for Laboratory Diagnosis, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China, Department of General Surgery, Wenzhou Hospital of Traditional Chinese Medicine, Wenzhou, Zhejiang 325000, P.R. China
Published online on: March 24, 2015 https://doi.org/10.3892/mmr.2015.3546
Pages: 1584-1590

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

It has been demonstrated that liver microRNA-125a-5p (miR-125a-5p) is correlated with disease progression in different liver diseases, including liver fibrosis and hepatocellular carcinoma (HCC). The present study investigated whether serum miR‑125a‑5p correlated with the progression of different liver diseases. Serum samples were obtained from healthy individuals, patients with chronic hepatitis B who had undergone a liver biopsy, and patients with HCC and were analyzed for the levels of miR‑125a‑5p. Compared with the healthy controls, the serum levels of miR‑125a‑5p were significantly higher in the liver fibrosis serum, and were reduced in HCC. With the development of liver fibrosis, there was a significant increase in the expression of miR‑125a‑5p (P<0.05). In comparing histological activity index (HAI) scores, higher expression levels of miR‑125a‑5p were observed in the high HAI score group (P<0.05). Furthermore, correlation between serum miR‑125a‑5p and viral replication (P<0.001) was observed. Notably, miR‑125a‑5p demonstrated significant correlation with other markers in the liver fibrosis group (P<0.001). In the patients with HCC, lower serum levels of miR‑125a‑5p were correlated with a poor prognosis, determined by Kaplan‑Meier curve analysis (P=0.009). In the liver fibrosis and HCC groups, different expression levels of serum miR‑125a‑5p were observed, and were correlated with disease progression. The results of the present study suggested that serum miR-125a-5p may be used as a non‑invasive biomarker for monitoring disease progression in liver diseases.

View Figures

View References

1	Ambros V: The functions of animal microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
2	Li L, Guo Z, Wang J, Mao Y and Gao Q: Serum miR-18a: a potential marker for hepatitis B virus-related hepatocellular carcinoma screening. Dig Dis Sci. 57:2910–2916. 2012. View Article : Google Scholar : PubMed/NCBI
3	Ding J, Huang S, Wu S, et al: Gain of miR-151 on chromosome 8q24.3 facilitates tumour cell migration and spreading through downregulating RhoGDIA. Nat Cell Biol. 12:390–399. 2010. View Article : Google Scholar : PubMed/NCBI
4	Bi Q, Tang S, Xia L, et al: Ectopic expression of MiR-125a inhibits the proliferation and metastasis of hepatocellular carcinoma by targeting MMP11 and VEGF. PloS One. 7:e401692012. View Article : Google Scholar : PubMed/NCBI
5	Coppola N, Potenza N, Pisaturo M, et al: Liver microRNA has-miR-125a-5p in HBV chronic infection: correlation with HBV replication and disease progression. PLoS One. 8:e653362013. View Article : Google Scholar
6	Chen X, Ba Y, Ma L, et al: Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 18:997–1006. 2008. View Article : Google Scholar : PubMed/NCBI
7	Fang C, Zhu DX, Dong HJ, et al: Serum microRNAs are promising novel biomarkers for diffuse large B cell lymphoma. Annals Hematol. 91:553–559. 2012. View Article : Google Scholar
8	Gilad S, Meiri E, Yogev Y, et al: Serum microRNAs are promising novel biomarkers. PLoS One. 3:e31482008. View Article : Google Scholar : PubMed/NCBI
9	Mitchell PS, Parkin RK, Kroh EM, et al: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 105:10513–10518. 2008. View Article : Google Scholar : PubMed/NCBI
10	Kim KH, Kim ND and Seong BL: Discovery and development of anti-HBV agents and their resistance. Molecules. 15:5878–5908. 2010. View Article : Google Scholar : PubMed/NCBI
11	Liu X, Wan X, Li Z, Lin C, Zhan Y and Lu X: Golgi protein 73 (GP73), a useful serum marker in liver diseases. Clin Chem Lab Med. 49:1311–1316. 2011. View Article : Google Scholar : PubMed/NCBI
12	Chen CJ, Yang HI, Su J, et al: Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 295:65–73. 2006. View Article : Google Scholar : PubMed/NCBI
13	2004 guidelines for surgical treatment of primary hepatocellular carcinoma. Chinese Journal of Hepatology. 13:329–330. 2005.PubMed/NCBI
14	Ishak K, Baptista A, Bianchi L, et al: Histological grading and staging of chronic hepatitis. J Hepatol. 22:696–699. 1995. View Article : Google Scholar : PubMed/NCBI
15	Yao J, Liang L, Huang S, et al: MicroRNA-30d promotes tumor invasion and metastasis by targeting Galphai2 in hepatocellular carcinoma. Hepatology. 51:846–856. 2010.PubMed/NCBI
16	Lau DT and Bleibel W: Current status of antiviral therapy for hepatitis B. Therap Adv Gastroenterol. 1:61–75. 2008. View Article : Google Scholar : PubMed/NCBI
17	Bayram A, Erkilic S, Ozkur A, Bayram M and Sari I: Quantification of intrahepatic total hepatitis B virus DNA in chronic hepatitis B patients and its relationship with liver histology. J Clin Pathol. 61:338–342. 2008. View Article : Google Scholar
18	Yuen MF, Ng IO, Fan ST, et al: Significance of HBV DNA levels in liver histology of HBeAg and Anti-HBe positive patients with chronic hepatitis B. Am J Gastroenterol. 99:2032–2037. 2004. View Article : Google Scholar : PubMed/NCBI
19	European Association For The Study Of The Liver: EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol. 50:227–242. 2009. View Article : Google Scholar
20	Russo A and Potenza N: Antiviral effects of human microRNAs and conservation of their target sites. FEBS Lett. 585:2551–2555. 2011. View Article : Google Scholar : PubMed/NCBI
21	Potenza N, Papa U, Mosca N, Zerbini F, Nobile V and Russo A: Human microRNA hsa-miR-125a-5p interferes with expression of hepatitis B virus surface antigen. Nucleic Acids Res. 39:5157–5163. 2011. View Article : Google Scholar : PubMed/NCBI
22	Park SO, Kumar M and Gupta S: TGF-beta and iron differently alter HBV replication in human hepatocytes through TGF-beta/BMP signaling and cellular microRNA expression. PloS One. 7:e392762012. View Article : Google Scholar
23	Sekiya Y, Ogawa T, Yoshizato K, Ikeda K and Kawada N: Suppression of hepatic stellate cell activation by microRNA-29b. Biochem Biophys Res Commun. 412:74–79. 2011. View Article : Google Scholar : PubMed/NCBI
24	Vizzutti F, Arena U, Rega L and Pinzani M: Non invasive diagnosis of portal hypertension in cirrhotic patients. Gastroenterol Clin Biol. 32:80–87. 2008. View Article : Google Scholar : PubMed/NCBI
25	Xie SB, Yao JL, Zheng RQ, Peng XM and Gao ZL: Serum hyaluronic acid, procollagen type III and IV in histological diagnosis of liver fibrosis. Hepatobiliary Pancreat Dis Int. 2:69–72. 2003.PubMed/NCBI
26	Parsian H, Rahimipour A, Nouri M, et al: Serum hyaluronic acid and laminin as biomarkers in liver fibrosis. J Gastrointestin Liver Dis. 19:169–174. 2010.PubMed/NCBI
27	Lydatakis H, Hager IP, Kostadelou E, Mpousmpoulas S, Pappas S and Diamantis I: Non-invasive markers to predict the liver fibrosis in non-alcoholic fatty liver disease. Liver Int. 26:864–871. 2006. View Article : Google Scholar : PubMed/NCBI
28	Ahmed F, Perz JF, Kwong S, Jamison PM, Friedman C and Bell BP: National trends and disparities in the incidence of hepatocellular carcinoma, 1998–2003. Prev Chronic Dis. 5:A742008.
29	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar : PubMed/NCBI
30	Qi P, Cheng SQ, Wang H, Li N, Chen YF and Gao CF: Serum microRNAs as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection. PLoS One. 6:e284862011. View Article : Google Scholar : PubMed/NCBI